BRAFTOVI encorafenib

Drug Class

BRAF kinase inhibitor

Mechanism

Encorafenib targets BRAF V600E and V600K kinases, inhibiting downstream MAPK pathway activation and reducing cancer cell growth.

Approved Indication

Treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, in combination with cetuximab, after prior therapy; treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with binimetinib.

What This Means For Patients

BRAFTOVI is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2018) — Sources
• EMA — Approved (2018) — Sources
• NMPA — Approved (2025) — Sources

Pivotal Clinical Evidence

• BEACON CRC — Kopetz et al., N Engl J Med 2019 (NCT02928224) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi
• https://doi.org/10.1056/NEJMoa1908075